Jushi Holdings (JUSHF) Common Equity (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Common Equity of -$141.8 million for Q2 2026, down 82.2% year-over-year from -$796.5 million in Q2 2025, and down 5.21% quarter-over-quarter from -$134.8 million in Q1 2026.
Jushi Holdings (JUSHF) Common Equity (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Common Equity for 6 consecutive years, with -$141.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 82.2% year-over-year to -$141.8 million; the TTM figure through Jun 2026 stood at -$141.8 million (down 82.2% YoY), while the FY2025 annual figure was -$115.3 million, down 129.61% from the prior year.
- Common Equity slipped to -$141.8 million in Q2 2026 per JUSHF's latest filing, from -$134.8 million in the prior quarter.
- Across five years, Common Equity topped out at $224.1 million in Q2 2022 and bottomed at -$141.8 million in Q2 2026.
- Historically, Common Equity has averaged -$3.9 million across 5 years, with a median of -$23.7 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 169.63% — and 2024, when it tumbled 593.95%.
- Jushi Holdings' Common Equity stood at $45.9 million in 2022, then sank by 116.6% to -$7.6 million in 2023, then sank by 559.34% to -$50.2 million in 2024, then tumbled by 129.61% to -$115.3 million in 2025, then fell by 22.95% to -$141.8 million in 2026.
- Business Quant data shows JUSHF's Common Equity at -$141.8 million in Q2 2026, -$134.8 million in Q1 2026, and -$115.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 4.05 Bn |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | -141.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141.82 Mn |
| Mar 31, 2026 | -134.80 Mn |
| Dec 31, 2025 | -115.34 Mn |
| Sep 30, 2025 | -101.47 Mn |
| Jun 30, 2025 | -77.84 Mn |
| Mar 31, 2025 | -65.88 Mn |
| Dec 31, 2024 | -50.24 Mn |
| Sep 30, 2024 | -38.69 Mn |
| Jun 30, 2024 | -23.78 Mn |
| Mar 31, 2024 | -23.59 Mn |
| Dec 31, 2023 | -7.62 Mn |
| Sep 30, 2023 | 7.83 Mn |
| Jun 30, 2023 | 27.48 Mn |
| Mar 31, 2023 | 35.76 Mn |
| Dec 31, 2022 | 45.89 Mn |
| Sep 30, 2022 | 177.46 Mn |
| Jun 30, 2022 | 224.10 Mn |
| Mar 31, 2022 | 193.16 Mn |
| Dec 31, 2021 | 180.98 Mn |
| Sep 30, 2021 | 165.95 Mn |